Details checkedClinical trial listing onlyCheckedregistry

Northwestern Statin Add-On Study for Sudden Sensorineural Hearing Loss

Also known as: Statin, HMG-coA reductase inhibitor, Oral Statins and Protection From Hearing Loss, Towards a Self-Administered Hearing Protection Regimen, NCT04826237

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 4

Status

Active

Target Gene

—

Route / Mode

Oral statin adjunct to corticosteroid standard care

Confidence

84%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

United States

Population

adult, sudden, sensorineural

Trial IDs

Mechanism

Recruiting Phase 4 study evaluating oral statin add-on therapy with standard methylprednisolone and rescue intratympanic dexamethasone versus placebo plus standard care in sudden sensorineural hearing loss.

Indications

Hearing Loss Sensorineural Hearing Loss Sudden Sensorineural Hearing Loss

Notes

Verified as a focused Northwestern statin add-on study now split out from the broad dexamethasone cluster. Methylprednisolone and dexamethasone are standard-care/rescue components in both arms and should not be presented as separate products from this trial.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT04826237

Open

Key Events

2023-02-09

Registry lists actual start for oral statin add-on study in sudden sensorineural hearing loss

Clinical Trials (1)

NCT04826237

Data Checks